Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist
Open Access
- 1 November 2018
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (11), 5367-5377
- https://doi.org/10.1111/jcmm.13809
Abstract
Nonpeptide thrombopoietin receptor (TPOR/MPL) agonists, such as eltrombopag, have been used to treat thrombocytopenia of various aetiologies. Here, we investigated the pharmacological properties of hetrombopag, a new orally active small-molecule TPOR agonist, in preclinical models. Hetrombopag specifically stimulated proliferation and/or differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells, with low nanomolar EC50 values through stimulation of STAT, PI3K and ERK signalling pathways. Notably, hetrombopag effectively up-regulated G(1)-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalized progression of the cell cycle, and prevented apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Moreover, hetrombopag and TPO acted additively in stimulating TPOR-dependent signalling, promoting cell viability, and preventing apoptosis. Orally administered hetrombopag specifically promoted the viability and growth of 32D-MPL cells in hollow fibres implanted into nude mice with much higher potency than that of the well-known TPOR agonist, eltrombopag, in association with activation of TPOR-dependent signal transduction in vivo. Taken together, our findings indicate that, given its favourable pharmacological characteristics, hetrombopag may represent a new, orally active, small-molecule TPOR agonist for patients with thrombocytopenia.Funding Information
- National Natural Science Foundation of China (81273546)
This publication has 38 references indexed in Scilit:
- A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonistsExperimental Hematology, 2012
- Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce plateletsThe Journal of Experimental Medicine, 2011
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 studyThe Lancet, 2011
- Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor AgonistThe International Journal of Cell Cloning, 2009
- Use of the in Vivo Hollow Fiber Assay in Natural Products Anticancer Drug DiscoveryJournal of Natural Products, 2009
- The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesisHaematologica, 2008
- Programmed Anuclear Cell Death Delimits Platelet Life SpanCell, 2007
- Recombinant human thrombopoietin: basic biology and evaluation of clinical studiesBlood, 2002
- Thrombopoietin, c‐Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists‐induced aggregation in platelets in vitroFEBS Letters, 1995
- Thrombocytopenia in c-mpl-deficient miceScience, 1994